TrialBMC cancer2014
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.
Alfredo Berruti et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
42 papers cite it
this paperpooled ittrialcites it